ArriVent Shares Plunge After Trial Failure of China-Licensed Drug
ArriVent BioPharma shares dropped nearly 47 percent after its cancer treatment firmonertinib failed to meet its primary goal in a phase 3 trial.
ArriVent BioPharma shares dropped nearly 47 percent after its cancer treatment firmonertinib failed to meet its primary goal in a phase 3 trial.